Evidence map›Paper›PMID 29526843›Full record

ArticleCancer biomarkers : section A of Disease markers2018

LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.

Libin Wang, Feng Wang, Li Na, Jingjing Yu, Liya Huang, Zhi-Qiang Meng, Zhen Chen, Hao Chen, Liu-Lu Ming, Yong-Qiang Hua

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Libin WangDepartment of Beijing National Biochip Research Center Sub-Center in Ningxia, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
Feng WangDepartment of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
Li NaDepartment of Biobank, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
Jingjing YuDepartment of Beijing National Biochip Research Center Sub-Center in Ningxia, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
Liya HuangDepartment of Gastroenterology, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China.
Zhi-Qiang MengMinimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhen ChenMinimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hao ChenMinimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Liu-Lu MingMinimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yong-Qiang HuaMinimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ningxia Medical University · CNFudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent study revealed that abnormal long noncoding RNAs (lncRNAs) expression are association with chemotherapy resistance of pancreatic ductal adenocarcinoma (PDAC).

objectiveThe present study was aimed to investigate the effects of lncRNA AB209630 expression for gemcitabine resistance in PDAC cells.

methodsIn the study, increased expression of lncRNA AB209630 could suppress cell proliferation and cell colony formation ability in gemcitabine resistance cells of PDAC. Furthermore, western blot results demonstrated that upregulation of lncRNA AB209630 suppressed the PI3K/AKT signaling pathway in gemcitabine resistance cells. Besides, we found that lncRNA AB209630 expression was dramatically downregulated in PDAC tissues compared to adjacent normal tissues. Lower PDAC expression predicted a poor prognosis in PDAC patients.

conclusionsThus, these results indicated that lncRNA AB209630 may be a potential target of PDAC.

Indexed as

Antimetabolites, AntineoplasticCarcinoma, Pancreatic DuctalCell Line, TumorCell ProliferationDeoxycytidineDown-RegulationDrug Resistance, NeoplasmFemaleGemcitabineHumansMalePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPrognosisProto-Oncogene Proteins c-aktRNA, Long NoncodingAntimetabolites, AntineoplasticDeoxycytidineGemcitabinelong non-coding RNA AB209630, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktRNA, Long NoncodingAB209630gemcitabine resistancelong non-coding RNAPancreatic ductal adenocarcinomaPI3K/AKT signaling

Identifiers

PMID29526843
PMCPMC13078444
OpenAlexW2791431314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.